Table 3 Adverse events of neoadjuvant HER2-targeted treatment
Adverse Events (AEs) | Total | TCbHP(n = 130) | AC/EC-THP(n = 46) | others(n = 3) | ||||
|---|---|---|---|---|---|---|---|---|
|  | All grades | Grade3 ~ 4 | All grades | Grade3 ~ 4 | All grades | Grade3 ~ 4 | All grades | Grade3 ~ 4 |
Leukopenia | 42(23.5%) | 9(5.0%) | 35(26.9%) | 4(3.1%) | 6(13.0%) | 1(2.2%) | 1(33.3%) | 1(33.3%) |
Neutropenia | 37(20.7%) | 11(6.1%) | 31(23.8%) | 9(6.9%) | 5(10.9%) | 1(2.2%) | 1(33.3%) | 1(33.3%) |
Thrombocytopenia | 26(14.5%) | 6(3.4%) | 25(19.2%) | 5(3.8%) | 0 | 0 | 1(33.3%) | 0 |
Anemia | 111(62.0%) | 4(2.2%) | 90(69.3%) | 4(3.1%) | 19(41.3%) | 0 | 2(66.7%) | 0 |
LEVF decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Transaminase increase | 21(11.7%) | 4(2.2%) | 17(13.1%) | 1(0.8%) | 3(6.5%) | 2(4.3%) | 1(33.3%) | 0 |
Creatinine increase | 4(2.2%) | 1(0.6%) | 3(2.3%) | 0 | 1(2.2%) | 1(2.2%) | 0 | 0 |